📊 Backtest📒 Journal Updated 13/08/2026
← 🔥 Turbo
📐 Simulate Position
STALE?Report written 14 days ago · at $29.95entry levels may be stale — re-check before acting

VERA

ค่าขนมMID CAP
Vera Therapeutics, Inc. · NASDAQ · Healthcare / Biotechnology (Nephrology)
$29.95
▼ 7.07%
MCap $2.31B
Down 7.07% today on a Q1 EPS miss (-$1.69 vs -$1.37 consensus) reported alongside earnings — commercial-launch spend, not a thesis change. Now $2.31B market cap, well off the 52-week high ($56.05) and down ~17% just since the last check two weeks ago.
BusinessKidney-disease biotech · TRUTAKNA (atacicept) won FDA accelerated approval Jul 7, 2026 for high-risk IgA nephropathy · Phase 3 ORIGIN eGFR analysis moved up to Q3 2026 ahead of a Q4 sBLA for full approval
Thesis

Vera already cleared its biggest hurdle: TRUTAKNA (atacicept) won FDA accelerated approval on Jul 7, 2026 for high-risk IgA nephropathy — a real, completed regulatory win, not a pending binary. Today's -7.07% drop is a Q1 EPS miss (-$1.69 vs -$1.37 consensus) tied to early commercial-launch spend, not a change to the underlying regulatory or clinical story — though a CRO leadership transition (William Turner retiring to advisor, Nancy Boman succeeding) adds a mild, unrelated distraction. The real near-term catalyst is unchanged: the FDA-agreed, moved-up ORIGIN Phase 3 eGFR analysis lands Q3 2026, setting up a Q4 sBLA for full (non-accelerated) approval. At $29.95 the 12-month consensus of $81.79 (14 analysts, Strong Buy) implies +173%, and the highest named target ($110) implies +267% — both unchanged in dollar terms from two weeks ago, so the percentage upside has simply grown as the price fell.

📝 Primary Verdict · Core Holding
SPECULATIVEค่าขนม

ค่าขนม — small-to-moderate position on an already-approved drug with a real, accelerated Q3 2026 confirmatory readout ahead. Today's EPS miss is a launch-spend story, not a thesis break, and the pullback improves the entry.

88
score / 100 ⓘ
⚡ Catalyst
🧬 ORIGIN Phase 3 eGFR Analysis (moved up)Q3 2026

Vera reached agreement with the FDA to accelerate the primary eGFR (kidney function) analysis from its ORIGIN Phase 3 trial to Q3 2026, ahead of the prior 2027 schedule — this data underpins the case for full (non-accelerated) approval.

Q3 2026
📄 sBLA Filing for Full ApprovalQ4 2026

Vera aims to file a supplemental Biologics License Application in Q4 2026 to convert TRUTAKNA's accelerated approval into full approval for IgA nephropathy, contingent on the Q3 eGFR data supporting it.

Q4 2026
🚀 TRUTAKNA Commercial LaunchONGOING

Already-launched commercial rollout for TRUTAKNA (available within weeks of the Jul 7 approval) — today's Q1 EPS miss shows real launch-phase spend; the market's near-term read on how fast this converts into prescriptions and revenue.

Ongoing
🎯 Entry Point
Entry 1
$29.95
Current price — post-EPS-miss, well off the 52-week high despite the FDA approval already wonScale in (small)
Entry 2PREFERRED
$26–28
Below today's post-miss level — best R/R if launch-spend skepticism persists into Q3If dips
Entry 3
$20.00
Deep dip — near the 52-week low ($19.07), only on a broad biotech selloff or further launch-execution disappointmentDeep dip only
✅ Take Profit
TP1
Base — commercial launch stabilizes, Q3 data awaited without incident
$52.41
+75%
TP2
Bull — positive Q3 eGFR data supports the full-approval case, hits consensus average
$81.79
+173.1%
TP3 🌙
Moon — clean Q3 data + launch spend converts to real revenue growth + full approval trajectory confirmed, hits the highest named target
$110
+267.3%
🔴 Stop Loss
Tight Stop
Below the post-earnings-miss support — thesis-neutral but launch-spend concerns deepening
$24.5
-18.2%
Hard Stop
Near the 52-week low — would suggest a genuinely disappointing Q3 readout or a failed commercial launch
$19
-36.6%
Risk / Reward
From Entry 2 ($27.00 mid) tight stop vs TP2
9.5 : 1
⚠ Strong R/R for an already-de-risked (approved) biotech — Moon case relies on a single high analyst target, treat cautiously
📅 Estimate Date
ORIGIN Phase 3 eGFR Analysis
Moved up from 2027 by FDA agreement — underpins the full-approval case
~Sep 15, 2026
Binary trial readout
sBLA Filing (Full Approval)
Contingent on Q3 data
Q4 2026
Would convert accelerated to full approval
📈 Possible Up % — Scenario Spread
Bear
-35%
$19.47
Base
+75%
$52.41
Bull
+173.1%
$81.79
Moon
+267.3%
$110
← downsideupside →
🏛️ Fed / Macro Risk — LOW

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook
Fed held at 3.50-3.75% on Jul 29 with 3 hawkish dissents favoring a hike — rate-hike tail risk into year-end hasn't gone away
Inflation
Core PCE still 3.3% YoY, well above the 2% target
Sector Impact
The Q3 eGFR readout and commercial launch execution are both largely macro-independent — clinical trial data and physician prescribing behavior don't respond to interest rates
Summary
LOW — this remains one of the more macro-independent names on the board since the core catalysts are clinical/regulatory/commercial execution rather than financing-dependent, and the company already has an approved, revenue-generating product
🎯 Analyst Targets

Wall Street price targets vs the current price — cross-check our TP levels

Consensus (14 analysts)
Strong Buy$81.79+173%
Highest named target
Buy$110+267%
Guggenheim (prior update)
Buy$61+104%
current price $29.95
🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

VERA✅ GoodJul 7, 2026
+7.05%
in 1 day
FDA accelerated approval for TRUTAKNA in high-risk IgA nephropathy
Same-company precedent for the core regulatory catalyst already realized — a real but muted single-day reaction, and today's EPS-miss selloff confirms the market is waiting for commercial proof, not just the approval headline.
CELC❌ BadJul 15, 2026
-16%
in 1 day
REVTORPYK (gedatolisib) FDA approval, followed by delayed launch-timeline guidance
A directly comparable pattern — a clean FDA approval still produced a sharp drop once management guided a slower commercial launch than expected, the exact risk VERA's own launch-spend miss today touches on.
KPTI❌ BadAug 2026
-69%
in 1 day
Phase 3 XPORT-EC-042 endometrial cancer trial primary-endpoint miss
The sector base rate for a genuine confirmatory Phase 3 miss — shows how much worse a disappointing Q3 2026 ORIGIN eGFR readout could be for VERA relative to the milder launch-timeline risk above.
⚡ Optional Layer · Tactical Overlay
🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-18% / -30%) only when trading the earnings spot — not for the core holding (use the -18.2% / -36.6% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern
modest pre-decision gains, reported specifically for VERA ahead of its Jul 7 approvalmulti-day runup into the confirmed decision date, then a further reaction on the actual approval

Vera's stock rose ahead of the Jul 7, 2026 FDA decision as anticipation built — a real pre-event runup pattern for this specific name.

🎲Historical Post-Catalyst Move
✅ Catalyst Winavg +15%
range: +7% to +30%· Jul 2026 (VERA approval)
VERA's own Jul 7, 2026 accelerated approval drove a +7.05% single-day gain — a real but muted re-rate that shows the market wanted commercial proof before fully pricing in the win, a read reinforced by today's EPS-miss selloff.
❌ Catalyst Missavg -35%
range: -16% to -69%· Jul 2026 (CELC) / Aug 2026 (KPTI)
Two relevant downside patterns: Celcuity (CELC) fell -15% to -17.6% on Jul 15, 2026 despite a clean FDA approval, purely on a delayed commercial-launch timeline guide — the exact 'approved but market wants launch proof' risk VERA faces; a genuine confirmatory Phase 3 miss can be far worse, as Karyopharm (KPTI) fell -69% on an Aug 2026 Phase 3 primary-endpoint miss.
💼Spot Position Sizing
How the recommended % is derived
4%
of portfolio

Mid-cap ($2.31B) biotech with an already-approved product (lower survival/binary risk than a pre-approval name) but real commercial-execution and confirmatory-trial uncertainty ahead — 4% sizing reflects the reduced-but-real risk profile

🛑Stop Loss · Spot Trade
Spot cut-loss levels — separate from the core holding
Before Catalyst
-18%($24.5)
Below the post-earnings-miss support zone ahead of Q3 data — thesis-neutral but launch-execution concerns deepening
After Catalyst (Bad Result)-30%
If the Q3 eGFR analysis disappoints or commercial launch metrics keep showing weak uptake, exit
📎 Sources

Generated 2026-08-05 · Not financial advice